ArticleThe Journal of clinical investigation2019
Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.
Article in The Journal of clinical investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- The effect of the HMGB1/RAGE/TLR4/NF-κB signalling pathway in patients with idiopathic epilepsy and its relationship with toxoplasmosis.Journal of cellular and molecular medicine · 2024Article
- Serum biomarkers of hypoxic-ischemic brain injury.Physiological research · 2023Review
- Glycyrrhizin regulates the HMGB1/P38MAPK signalling pathway in status epilepticus.Molecular medicine reports · 2023Article
- Neuroinflammation in epileptogenesis: from pathophysiology to therapeutic strategies.Frontiers in immunology · 2023Review
- Reappraisal of oxidized HMGB1 as a mediator and biomarker.Future science OA · 2022Review
- Characterization and Quantification of Oxidized High Mobility Group Box 1 Proteoforms Secreted from Hepatocytes by Toxic Levels of Acetaminophen.Chemical research in toxicology · 2022Article
- Molecular insights into the multifaceted functions and therapeutic targeting of high mobility group box 1 in metabolic diseases.Journal of cellular and molecular medicine · 2022Review
- Role of HMGB1/TLR4 and IL-1β/IL-1R1 Signaling Pathways in Epilepsy.Frontiers in neurology · 2022Review
- Cattle BileFrontiers in pharmacology · 2022Article
- Expression of HMGB1 and TLR4 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders.Annals of translational medicine · 2020Article
Corrections and comments
- Retraction of
Authors and funding
18 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.